Intellia Therapeutics Announces Proposed Public Offering of Common Stock
November 01 2017 - 6:00AM
Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing
company focused on the development of potentially curative
therapeutics using CRISPR/Cas9 technology, today announced that it
has commenced an underwritten public offering of $150 million of
its common stock. Intellia also intends to grant the underwriters a
30-day option to purchase up to an additional fifteen percent (15%)
of the shares of common stock offered in the public offering. All
of the shares in the proposed offering are to be sold by Intellia.
Credit Suisse, Jefferies LLC, and Leerink Partners are acting as
joint book-running managers of the proposed offering. The offering
is subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
The shares are being offered by Intellia pursuant to a shelf
registration statement that was previously filed with, and
subsequently declared effective by, the U.S. Securities and
Exchange Commission (SEC). A preliminary prospectus supplement
relating to and describing the terms of the offering will be filed
with the SEC and will be available on the SEC’s website at
www.sec.gov. Copies of the preliminary prospectus supplement and
the accompanying prospectus relating to these securities may be
obtained, when available, from: Credit Suisse Securities (USA) LLC,
Attn: Prospectus Dept., One Madison Avenue, New York, NY 10010, by
telephone at (800) 221-1037 or by email at
newyork.prospectus@credit-suisse.com; Jefferies LLC, Attn: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, by telephone at 877-547-6340 or by email at
Prospectus_Department@Jefferies.com; or Leerink Partners LLC, Attn:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at 800-808-7525 ext. 6132 or by email
at Syndicate@Leerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system.
Forward-Looking StatementsThis press release
contains "forward-looking statements" of Intellia within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, but are not limited to,
those relating to Intellia’s expectations regarding the completion,
timing and size of the public offering, and its expectations with
respect to granting the underwriters a 30-day option to purchase
additional shares. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
of future events, and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties related
to completion of the proposed public offering on the anticipated
terms, or at all, include, but are not limited to, market
conditions and the satisfaction of customary closing conditions
related to the proposed public offering. For a discussion of these
and other risks and uncertainties, and other important factors, any
of which could cause Intellia’s actual results to differ from those
contained in the forward-looking statements, see the section
entitled “Risk Factors” in Intellia’s most recent annual report on
Form 10-K and quarterly report on Form 10-Q filed with
the SEC, as well as discussions of potential risks,
uncertainties, and other important factors in Intellia’s other
filings with the SEC, including those contained or
incorporated by reference in the preliminary prospectus supplement
related to the proposed public offering to be filed with the SEC.
All information in this press release is as of the date of the
release, and Intellia undertakes no duty to update this
information unless required by law.
Intellia Contacts:
Lindsey Trickett Vice President, Investor Relations +1
857-285-6211 lindsey.trickett@intelliatx.com
Jennifer Mound Smoter Senior Vice President, External Affairs
& Communications +1 857-706-1071 jenn.smoter@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024